Testosterone differentially regulates targets of lipid and glucose metabolism in liver, muscle and adipose tissues of the testicular feminised mouse

被引:0
作者
Daniel M. Kelly
Samia Akhtar
Donna J. Sellers
Vakkat Muraleedharan
Kevin S. Channer
T. Hugh Jones
机构
[1] The University of Sheffield,Department of Oncology and Metabolism, Medical School
[2] Sheffield Hallam University,Biomolecular Research Centre
[3] Barnsley Hospital NHS Foundation Trust,Centre for Diabetes and Endocrinology
[4] Royal Hallamshire Hospital,Department of Cardiology
[5] Gold Coast,Present address: Faculty of Health Sciences and Medicine, Bond University
来源
Endocrine | 2016年 / 54卷
关键词
Type 2 diabetes; Metabolism; Testosterone; Androgen receptor; Adipose tissue;
D O I
暂无
中图分类号
学科分类号
摘要
Testosterone deficiency is commonly associated with obesity, metabolic syndrome, type 2 diabetes and their clinical consequences—hepatic steatosis and atherosclerosis. The testicular feminised mouse (non-functional androgen receptor and low testosterone) develops fatty liver and aortic lipid streaks on a high-fat diet, whereas androgen-replete XY littermate controls do not. Testosterone treatment ameliorates these effects, although the underlying mechanisms remain unknown. We compared the influence of testosterone on the expression of regulatory targets of glucose, cholesterol and lipid metabolism in muscle, liver, abdominal subcutaneous and visceral adipose tissue. Testicular feminised mice displayed significantly reduced GLUT4 in muscle and glycolytic enzymes in muscle, liver and abdominal subcutaneous but not visceral adipose tissue. Lipoprotein lipase required for fatty acid uptake was only reduced in subcutaneous adipose tissue; enzymes of fatty acid synthesis were increased in liver and subcutaneous tissue. Stearoyl-CoA desaturase-1 that catalyses oleic acid synthesis and is associated with insulin resistance was increased in visceral adipose tissue and cholesterol efflux components (ABCA1, apoE) were decreased in subcutaneous and liver tissue. Master regulator nuclear receptors involved in metabolism—Liver X receptor expression was suppressed in all tissues except visceral adipose tissue, whereas PPARγ was lower in abdominal subcutaneous and visceral adipose tissue and PPARα only in abdominal subcutaneous. Testosterone treatment improved the expression (androgen receptor independent) of some targets but not all. These exploratory data suggest that androgen deficiency may reduce the buffering capability for glucose uptake and utilisation in abdominal subcutaneous and muscle and fatty acids in abdominal subcutaneous. This would lead to an overspill and uptake of excess glucose and triglycerides into visceral adipose tissue, liver and arterial walls.
引用
收藏
页码:504 / 515
页数:11
相关论文
共 246 条
[1]  
Jones TH(2010)Testosterone deficiency: a risk factor for cardiovascular disease? Trends Endocrinol. Metab. 21 496-503
[2]  
Kelly DM(2013)Testosterone: a metabolic hormone in health and disease. J. Endocrinol. 217 R25-R45
[3]  
Jones TH(1992)The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int. J. Obes. 16 991-997
[4]  
Mårin P(2005)Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 28 1636-1642
[5]  
Holmäng S(2015)The emancipation of testosterone from niche hormone to multi-system player Asian J. Androl. 17 58-60
[6]  
Jönsson L(2008)Testosterone for the aging male; current evidence and recommended practice. Clin. Interv. Aging 3 25-44
[7]  
Sjöström L(2011)Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 Diabetes 34 1669-1675
[8]  
Kvist H(2011)Cardiovascular risk during androgen deprivation therapy for prostate cancer. Br. Med. J. 342 d3105-3318
[9]  
Holm G(2004)The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J. Clin. Endocrinol. Metab. 89 3313-906
[10]  
Lindstedt G(2006)Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur. J. Endocrinol. 154 899-612